Media stories about Acer Therapeutics (NASDAQ:ACER) have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acer Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.4227099929231 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
ACER traded up $0.61 during midday trading on Friday, hitting $19.04. The stock had a trading volume of 20,247 shares, compared to its average volume of 20,519. The firm has a market cap of $138.18, a P/E ratio of -4.96 and a beta of 2.32. Acer Therapeutics has a 1 year low of $5.69 and a 1 year high of $22.63.
Acer Therapeutics (NASDAQ:ACER) last released its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.10). equities research analysts anticipate that Acer Therapeutics will post -3.22 EPS for the current year.
Several brokerages have recently commented on ACER. Zacks Investment Research lowered Acer Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 9th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Acer Therapeutics in a research note on Friday, March 9th. Roth Capital initiated coverage on Acer Therapeutics in a research note on Monday, February 26th. They issued a “buy” rating and a $70.00 target price for the company. Finally, William Blair initiated coverage on Acer Therapeutics in a research note on Friday, February 16th. They issued an “outperform” rating for the company. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. Acer Therapeutics currently has an average rating of “Hold” and an average target price of $60.00.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/acer-therapeutics-acer-getting-somewhat-favorable-news-coverage-analysis-shows.html.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.